E-MTAB-6654 - Transcriptomic profiling of three different neuroblastoma cell lines (CLB-BAR, CLB-GE and SK-N-AS) in response to ALK inhibition

Last updated on 25 June 2018, released on 1 September 2018
Homo sapiens
Samples (17)
Protocols (4)
Anaplastic Lymphoma Kinase (ALK) is a tyrosine kinase receptor which is a clinical target of major interest in cancer, including neuroblastoma. To better understand ALK signaling, three different neuroblastoma cell lines (CLB-BAR, CLB-GE and SK-N-AS) were cultured for 1hr and 24hrs in control conditions or after treatment with the ALK inhibitors crizotinib or lorlatinib. RNA-Seq experiments were performed to determine the expression changes resulting from ALK inhibition. Together with parallel phosphoproteomic experiments, these data unveil several important conserved oncogenic pathways in neuroblastoma.
Experiment type
RNA-seq of coding RNA 
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals important conserved oncogenic pathways. Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik S, Ruuth K, Larsson E, Palmer R and Hallberg B.
Exp. designProtocolsVariablesProcessedSeq. reads
Investigation descriptionE-MTAB-6654.idf.txt
Sample and data relationshipE-MTAB-6654.sdrf.txt